Definium Therapeutics Inc (DFTX) Leerink Global Healthcare Conference 2026 summary

Company overview and strategy

• Rebranded to Definium Therapeutics for distinctiveness and easier recognition as commercialization nears.

• Focused on precision and boundlessness, reflected in the new name.

• Grown from zero to about 120 employees in five years, with further growth expected.

• Lead asset DT120 is an ODT formulation of LSD for GAD and MDD, with three ongoing phase III studies.

• Second program, DT402 (R-enantiomer of MDMA), targets core symptoms of autism spectrum disorder.

Clinical program highlights

• DT120 phase II study showed a 22-point drop in HAM-A for GAD, 7.7 points better than placebo, and similar strong results in MDD.

• Dose response established, with 100 micrograms as the recommended dose for maximal efficacy and manageable side effects.

• Durability of effect observed for at least 12 weeks after a single dose, with half of patients in remission at 12 weeks.

• Phase III studies are ongoing, with pivotal data readouts expected in late Q2 and throughout the year.

• Functional unblinding addressed by including a subtherapeutic dose as a control, aligned with FDA guidance.

Market opportunity and commercialization

• GAD and MDD affect 50 million US adults, with significant unmet need and rising incidence.

• No new GAD drug approved since 2007; high provider and patient enthusiasm for new options.

• Commercialization strategy includes targeting 7,000 REMS-certified providers and supporting site readiness.

• Sites expected to be reimbursed $100–$150 per hour for patient monitoring during 8-hour sessions.

• Annual pricing expected to be in the $28,000–$70,000 range, comparable to Spravato, but with fewer required administrations.